|Cell culture supernatants||99%||92%-108%|
HER2, also known as ErbB2 and Neu, is a member of the epidermal growth factor (EGF) receptor family. Overexpression of HER2 have been reported in numerous cancers, including breast, ovarian, lung, gastric, and oral cancers. It is a therapeutic target for the treatment of breast cancer and other carcinomas. HER2 is a 185-kDa transmembrane glycoprotein, the extracellular domain (ECD) of which can be cleaved from the cell surface by matrix metalloproteases and then released into blood. Elevated serum HER2 levels are reported in 23% to 80% of patients with metastatic breast cancer. Raising serum HER2 levels have been correlated with indicators of poor prognosis and a poor response to chemotherapy.